NCT05262244View on ClinicalTrials.gov

Targeted Fluorescence Imaging in AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2024

Conditions
Age-Related Macular DegenerationNAMD
Interventions
DRUG

Bevacizumab-IRDye800CW

Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.

Trial Locations (1)

9713 GZ

University medical center Groningen (UMCG), Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER